Bosh sahifaEXEL • NASDAQ
add
Exelixis Inc
41,03 $
Seans yopilganidan keyin:(0,17%)+0,070
41,10 $
Yopilgan:2-mar, 19:12:21 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
44,06 $
Kunlik diapazon
39,71 $ - 43,25 $
Yillik diapazon
32,38 $ - 49,40 $
Bozor kapitalizatsiyasi
10,66 mlrd USD
Oʻrtacha hajm
2,70 mln
Narx/foyda
14,78
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 598,66 mln | 5,63% |
Joriy xarajat | 336,27 mln | -12,28% |
Sof foyda | 244,53 mln | 74,84% |
Sof foyda marjasi | 40,85 | 65,52% |
Har bir ulushga tushum | 0,94 | 70,91% |
EBITDA | 242,86 mln | 41,94% |
Amaldagi soliq stavkasi | 3,23% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,06 mlrd | -4,70% |
Jami aktivlari | 2,84 mlrd | -3,50% |
Jami passivlari | 683,10 mln | -2,90% |
Umumiy kapital | 2,16 mlrd | — |
Tarqatilgan aksiyalar | 259,71 mln | — |
Narxi/balansdagi bahosi | 5,35 | — |
Aktivlardan daromad | 20,81% | — |
Kapitaldan daromad | 25,10% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 244,53 mln | 74,84% |
Operatsiyalardan naqd pul | 333,52 mln | 38,81% |
Sarmoyadan naqd pul | 27,24 mln | 129,23% |
Moliyadan naqd pul | -254,57 mln | -35,38% |
Naqd pulning sof oʻzgarishi | 106,19 mln | 359,17% |
Boʻsh pul | 200,84 mln | 81,20% |
Haqida
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Tashkil etilgan
15-noy, 1994
Sayt
Xodimlar soni
1 077
